Publications by authors named "Caitlin S Rees"
J Crohns Colitis
December 2021
Article Synopsis
- The study aimed to evaluate the long-term effectiveness and safety of the adalimumab biosimilar SB5 in patients with inflammatory bowel disease (IBD), comparing those who switched from the ADA originator and those who started directly on SB5.
- A total of 481 IBD patients were analyzed, with 70.8% of those who switched to SB5 remaining on the treatment after a year, while 60.3% of new users also persisted beyond that timeframe.
- Overall, no significant changes in clinical outcomes were observed post-switch, suggesting that switching to SB5 is both effective and safe for long-term use in IBD patients.
